May 1, 2010

The FDA’s Perspective on the Risk for Rapid Rise in Hemoglobin in Treating CKD Anemia: Quo Vadis

.   .   

In response to the publication of “Trial to Reduce Cardiovascular Endpoints with Aranesp Therapy” (TREAT), the US Food and Drug Administration has elected to reevaluate the use of erythropoiesis-stimulating agents in the treatment of anemia secondary to chronic kidney disease. This commentary by Dr. Ajay Singh provides insight into the challenges involved with interpreting the current body of evidence in this controversial topic.

Related Articles:


Comments are closed.